Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24576662 | 1.00 | SLC7A5 (0.35) | SLC7A5MGLLDPP4HTR1ATBXA2R | |
| SCHEMBL8478185 | 1.00 | SLC7A5 (0.35) | SLC7A5MGLLDPP4HTR1ATBXA2R | |
| SCHEMBL13061953 | 0.85 | MGLL (0.34) | MGLLDPP4 | |
| SCHEMBL356572 | 0.85 | MGLL (0.34) | MGLLDPP4 | |
| SCHEMBL10869514 | 0.85 | MGLL (0.34) | MGLLDPP4 | |
| SCHEMBL14804761 | 0.83 | DPP4 (0.41) | DPP4 | |
| SCHEMBL7397688 | 0.83 | DPP4 (0.41) | DPP4 | |
| SCHEMBL22954473 | 0.81 | MGLL (0.34) | MGLL | |
| SCHEMBL13463250 | 0.81 | MGLL (0.34) | MGLL | |
| SCHEMBL12092206 | 0.81 | MGLL (0.34) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| CN-118846112-A | Cysteine engineered antibody-toxin conjugates and methods of making same | 四川百利药业有限责任公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-20150132324-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-8980824-B2 | Tubulysin compounds, methods of making and use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2014126836-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-21 | — | — | WO | disclosed |
| US-20140227295-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-14 | — | — | US | disclosed |
| US-20140227298-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-14 | — | — | US | disclosed |
| EP-1749007-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1680137-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | Intermune, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-5955501-A | DERIVED FROM PHORBOIDS OF THE DITERPENE- AND BENZOLACTAM-CLASSES. | PROCYON PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | SLC7A5 1202/4885MGLL 1184/4885DPP4 1982/4885 |
| US-20150132324-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | CCNB1, CCNB3, CCNB2 | SLC7A5 2274/4885MGLL 4835/4885DPP4 3888/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | SLC7A5 3261/4885MGLL 126/4885DPP4 225/4885 |
| US-20140227298-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | CCNB3, CCNB1, CCNB2 | SLC7A5 2237/4885MGLL 4844/4885DPP4 4179/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | SLC7A5 3261/4885MGLL 126/4885DPP4 225/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | SLC7A5 877/4885MGLL 1124/4885DPP4 1899/4885 |
| US-20140227295-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | CCNB1, CCNB3, CCNB2 | SLC7A5 2274/4885MGLL 4835/4885DPP4 3888/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | SLC7A5 3261/4885MGLL 126/4885DPP4 225/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | SLC7A5 3261/4885MGLL 126/4885DPP4 225/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | SLC7A5 2829/4885MGLL 196/4885DPP4 326/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | SLC7A5 3261/4885MGLL 126/4885DPP4 225/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | SLC7A5 3261/4885MGLL 126/4885DPP4 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.